The BEST trial is testing the hypothesis that beta blocker therapy can improve longevity of patients with congestive heart failure. Patients will receive either bucindolol, a beta blocker, or placebo in a randomized double-blind fashion and are assessed for a variety of endpoints, including: all cause mortality, total cardiovascular mortality, quality of life, hospitalizations, myocardial infarction, and the need for transplantation. Patient enrollment is active and will continue in the coming year.
Showing the most recent 10 out of 1232 publications